Clinical Trials Directory

Trials / Recruiting

RecruitingNCT02609685

Active Surveillance of Papillary Thyroid Microcarcinoma

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
216 (estimated)
Sponsor
Cedars-Sinai Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.

Detailed description

The incidence of thyroid cancer has more than doubled in the last 30 years in the United States, Europe, Canada, and South America. Since nearly 50% of this increase is attributable to papillary thyroid microcarcinomas (PTMC), it appears that greater detection and diagnosis of previously subclinical disease is a major factor driving this dramatic rise. The primary objective is to estimate the rate of disease progression (growth of primary tumor or development of loco-regional/distant metastases) over a 3, 5, and 10-year period in a series of PTMC patients followed with active surveillance in the United States. Patients who opt for immediate surgery can participate in a sub-study looking at quality of life and anxiety measures as compared to those patients who enroll in the active surveillance main study. Patients who enroll in active surveillance can choose to have surgery at any time that they and their treating physician feel that it is in their best interest.

Conditions

Interventions

TypeNameDescription
OTHERActive SurveillanceSubjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.

Timeline

Start date
2016-05-13
Primary completion
2030-12-01
Completion
2030-12-01
First posted
2015-11-20
Last updated
2025-09-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02609685. Inclusion in this directory is not an endorsement.